03/05/2023
💡 Can early intervention change live for children with genetic disorders? Meet Ayla Bashir, a 15-month-old miracle child and the first to receive medical treatment for her genetic disorder before birth 🎉👶.
Ayla's success has opened the door for more research in this area, but ethical questions abound. How do you feel about treating fetuses in clinical trials? 💭🤔
👩⚕️ Dr. Tippi MacKenzie, a pediatric and fetal surgeon at the University of California San Francisco, has been working on fetal enzyme replacement therapy to treat genetic diseases like Pompe disease, which Ayla has. Early treatment in fetuses can potentially prevent significant organ damage and increase their quality of life 🌟💊. But it's not without risks.
🤰 Are the risks worth the benefits? Pregnant individuals may face risks without direct health benefits, while fetuses may be exposed to significant or uncertain risks. What should be the acceptable risk threshold for these treatments? 📊❓
🚀 Ayla's story could pave the way for other medical therapies for fetuses with genetic diseases. However, Dr. MacKenzie is cautious about using newer or more experimental treatments in fetuses. Bioethicist Saskia Hendriks points out that there's a balancing act between collecting enough data on experimental therapies and delaying trials of potentially life-saving treatments 🧬⚖️.
https://www.technologyreview.com/2022/11/11/1063121/toddler-first-treated-before-born
🌈 Ayla's success is a beacon of hope for many families, but there's still a long way to go. What are your thoughts on the ethical questions raised by fetal medical treatments? Share your opinions in the comments! 🌟💬
Ayla's treatment may have saved her life. But testing experimental treatments in fetuses comes with ethical challenges.
